Xtag CYP2C19 Kit V3
by Luminex Molecular Diagnostics, Inc.
510(k) K131565
Xtag CYP2C19 Kit V3 is a medical device (FDA Class II; FDA product code NTI, Drug Metabolizing Enzyme Genotyping Systems) made by Luminex Molecular Diagnostics, Inc., cleared under FDA 510(k) K131565 on 11 Sep 2013, active as of 10 Oct 2026.
Active
510(k)
Valid until
No expiry
FDA recalls
None found
Documents
Trust
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK131565 | Date11 Sep 2013 | StatusActive |
Official records
- FDA 510(k) database K131565
From the FDA record
- Received by the FDA
- 30 May 2013
- FDA decision
- 11 Sep 2013 (Substantially Equivalent)
- FDA review time
- 104 days from receipt to decision
- Public document
- 510(k) statement on file with the FDA
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Specification
- 510(k) Number
- FDA product code
- NTI
- Device class
- Class II
- Regulation
- 21 CFR Part 862.3360
- Advisory committee
- Clinical Toxicology
- FDA decision
- SESE Substantially Equivalent
Devices cleared under K131565
Devices that FDA's GUDID lists as cleared or approved under this submission number. One submission usually covers a whole product family, so the sizes and models are listed here once.
| UDI-DI | Size and differences | |||
|---|---|---|---|---|
| xTAG® CYP2C19 Kit v3 I046B0427 | I046B0427 / I046B0427 | 00840487100172 | — | On the market |
Similar devices
Other devices filed under FDA product code NTI (Drug Metabolizing Enzyme Genotyping Systems).
- AMPLICHIP CYP450 TEST, MODEL 04381866190 by Roche Molecular System, Inc.
- ROCHE AMPLICHIP CYP450 TEST by Roche Molecular System, Inc.
- VERIGENE CYP2C19 NUCLEIC ACID TES (2C19) by NANOSPHERE, INC.
- INFINITI CYP2C19 ASSAY by AUTOGENOMICS, INCORPORATED
- INVADER UGT1A1 MOLECULAR ASSAY by Third Wave Technologies, Inc.
- Genomadix Cube CYP2C19 System by Genomadix, Inc.
- SPARTAN RX CYP2C19 TEST SYSTEM by Spartan Bioscience, Inc.